THURSDAY, March 25, 2021 -- For patients with acute posttraumatic headache presenting to the emergency department, intravenous metoclopramide + diphenhydramine (M+D) is more efficacious than placebo, according to a study published online March 24 in Neurology.
Benjamin W. Friedman, M.D., from the Albert Einstein College of Medicine in Bronx, New York, and colleagues randomly assigned 160 participants who experienced head trauma and presented to the emergency department within 10 days with a headache to either M+D or placebo in a double-blind trial. Overall, 81 and 79 participants were assigned to M+D and placebo, respectively.
The researchers found that the mean improvement in pain was 5.2 for participants receiving M+D compared with 3.8 for placebo participants (difference of 1.4 favoring M+D). Adverse events were reported by 43 and 28 percent of patients receiving M+D and placebo, respectively.
"More research is needed to determine the most effective dose of metoclopramide, and how long to administer it, to see if people can get longer-term relief after they leave the emergency room," Friedman said in a statement. "Also, future work may be able to determine whether early treatment with this medication can target other disruptive symptoms you may get after a head injury, like depression, sleep disorders, and anxiety."
Abstract/Full Text (subscription or payment may be required)
© 2021 HealthDay. All rights reserved.
Posted: March 2021
WEDNESDAY, March 24, 2021 -- In female veterans, posttraumatic stress disorder (PTSD) is associated with an increased risk for ischemic heart disease (IHD), especially for younger...
THURSDAY, March 11, 2021 -- Globally, among health care workers, there has been a high prevalence of depression, anxiety, and posttraumatic stress disorder (PTSD) during the...
THURSDAY, Jan. 14, 2021 -- Probable mental health disorders are common among intensive care unit (ICU) staff working in English hospitals during June and July 2020, according to a...
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.